Title

New anti-cancer drug

The new anti-cancer drug, OMO-1, was given to the first cancer patient in the world last week in Oxford University’s Early Phase trials unit. Dr Sarah Blagden (Oxford’s ECMC lead and Director of the Early Phase Trials Unit) is Chief Investigator of this Phase I/II study of the combined c-MET/ OCT-1 inhibitor OMO-1 that was outlicenced from Janssen Pharmaceutica to be developed by the Belgian life science company OCTIMET Oncology NV.

Dr Blagden says “it is great to be able to offer our patients new therapies that could be the game-changers of the future.” The centre will be enrolling patients with advanced cancer into this study until Q3, 2018. 

Timothy Perera, CEO of OCTIMET says “We are pleased to reach this important milestone within 7 months of obtaining funding. We look forward to accelerating the development of this agent so that we can bring another personalised therapeutic option for patients in areas of unmet medical need.”

The next patient to enter the study is due to start treatment, also in Oxford, later this week.

About Us
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
Research
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate training programmes for both scientists and clinicians are internationally recognised.